ライフサイエンスコーパス: cure

1 ose with pathogen eradication (microbiologic cure).

2 a sustained virological response (effective cure).

3 Mental health treatment may facilitate HCV cure.

4 HIV-1 latency is a major barrier to cure.

5 with bacterial pneumonia following clinical cure.

6 espread access to safe and effective radical cure.

7 d may require additional therapy for radical cure.

8 ents independently of liver fibrosis and HCV cure.

9 search and clinical trials directed at HIV-1 cure.

10 g implant warrants device removal to achieve cure.

11 propose that these findings represent HIV-1 cure.

12 esophagectomy patients, 32.5% had failure to cure.

13 nd an undisputed antiviral target for an HBV cure.

14 e been explored as a strategy towards an HIV cure.

15 debilitating condition for which there is no cure.

16 iral therapy (ART), remains a barrier to HIV cure.

17 e or more partner drugs that ensure complete cure.

18 d did not consistently recover following HCV cure.

19 ains the major barrier to disease control or cure.

20 y years and multiple rounds of infection and cure.

21 ion and as a contributor to a functional HIV cure.

22 e latent reservoir is a major barrier to HIV cure.

23 se liver disease progression, even after HCV cure.

24 some cases leading to surgery with intent to cure.

25 in some individuals, there is no vaccine or cure.

26 th bacterial pneumonia who achieved clinical cure.

27 C is necessary to ultimately achieve disease cure.

28 of the disease and a promising treatment or cure.

29 ems to be key for the spontaneous functional cure.

30 ) can control the virus, it does not provide cure.

31 associated with increased odds of functional cure.

32 ld inform immunomodulatory therapies for HBV cure.

33 tment, and the establishment of nonrelapsing cure.

34 therapy, long-term disease control, or even cure.

35 ed rates of ESLD, compared to those who were cured.

36 h started DAA treatment and 149 (99.3%) were cured.

37 , and only 2 (20% [95% CI, 2.5%-55.6%]) were cured.

38 tient's hypoparathyroidism to be permanently cured.

39 ectable intermittently for years after being cured.

40 ation, ultimately resulting in durable tumor cures.

41 for these cancers fail to provide long-term cures.

42 H-bonding containing monomer during network curing.

43 t 6 months of multidrug treatment to achieve cure(1).

44 Here, we investigated the effects of curing (37 degrees C for 3 days) and storage at low-temp

45 An intervention that successfully cured a reasonable fraction of adults would be sufficien

46 herapies are more likely to achieve complete cures, acquired resistance remains an obstacle to their

47 impact of ceftolozane/tazobactam on clinical cure, acute kidney injury (AKI), and in-hospital mortali

48 m was independently associated with clinical cure (adjusted odds ratio [aOR], 2.63; 95% confidence in

49 seroconversion during therapy and functional cure after therapy.

50 neutrophil activation characterize clinical cure after treatment of CL, supporting participation of

51 a diepoxy comonomer, and a dicarboxylic acid curing agent.

52 CBD's reputation as a cure-all puts it in the same class as other "natural" pa

53 the field of cancer treatment, the idea of a cure-all silver bullet has long been abandoned.

54 inhibitors, these modalities were unable to cure AML or significantly extend the lives of patients w

55 ulted in cure in 77 % (20/26) of cases, with cures among all species.

56 441 patients, 237 experienced microbiologic cure and 204 experienced microbiologic failure.

57 To-date, there is no effective cure and disease management relies on early detection an

58 DMD has no cure and few treatment options.

59 ugh technology is used responsibly to treat, cure and prevent genetic disease.

60 Rates of initial clinical cure and rCDI were summarized by eAb titer category (low

61 overlapping editing motif preferences, with CURE and RESCUE-S being uniquely able to edit UCC and AC

62 adicating NPM1-mutated clones to achieve AML cure and the impact of preleukemic clonal hematopoiesis

63 r novel therapeutic approaches targeting HIV cure and, more generally, suggest consideration of BCL-2

64 hich the causes and symptoms of diseases are cured and alleviated.

65 ently infected individuals who can be easily cured and optimization of treatment for those in whom tr

66 cal resection represents the only chance for cure, and advancements in adjuvant chemotherapy have imp

67 Latent HIV infection is the main barrier to cure, and most HIV-infected cells reside in the gut, whe

68 ory B cells (B(regs)) is able to ameliorate, cure, and sustain the durable remission of the disease.

69 -elimination program, 176/190 MSM (93%) were cured, and the HCV incidence rate declined from 0.53 per

70 scriptional inhibitors in block-and-lock HIV cure approaches.IMPORTANCE Antiretroviral therapy (ART)

71 Approaches for cure are lacking, and the knowledge of virus-host intera

72 Since cures are currently unavailable, major efforts in improv

73 The primary endpoint was clinical cure assessed at week 12 and included a composite of abs

74 ary outcome of the trial was microbiological cure at 24 hours on repeat culture.

75 ss all treatment groups achieved therapeutic cure at Day 28 in the VT-1161 and fluconazole groups.

76 with therapeutic (clinical and mycological) cure at Day 28.

77 fully understood and there is no LS-specific cure available to patients.

78 ve impairment is significantly improved with cure but not better than HIV infection alone, which stro

79 lar dose of gentamicin and underwent test of cure by culture 4-7 days later.

80 Both were cured by doxycycline treatment.

81 Here, we show that transplant sarcomas are cured by PD-1 blockade and radiotherapy, but identical t

82 rising in the absence of each chaperone were cured by restoring normal levels of that protein.

83 ac disease could be treated, and potentially cured, by restoring T-cell tolerance to gliadin.

84 In highly malignant ANECs, cure can in rare cases be achieved.

85 roots for the major challenge of effectively curing cancer patients.

86 yzed the lack of progress in explaining and "curing" cancer by examining the merits of the premises t

87 , while Treg targeting as a strategy for HIV cure cannot be discarded, the methodology for Treg deple

88 , and altering PQC abundance or activity can cure cells of prions.

89 se-based Undergraduate Research Experiences (CUREs) centered on genome annotation, and students to pa

90 d in clinical trials-their combination might cure chronic HBV infection.

91 years (QALY); cases identified, treated, and cured; cirrhosis cases avoided; incremental cost-effecti

92 tions in which a policy of universal radical cure, combining artemisinin-based combination therapy (A

93 CURE comprises the cytidine deaminase enzyme APOBEC3A fu

94 neic HSCT seems to be an effective option to cure cytopenia and severe autoinflammation in PAMI syndr

95 rogramming and highlighted the potential for curing degenerative retinal diseases from intrinsic cell

96 ortant to utilize pediatric models to inform cure-directed approaches for HIV-1-infected children.

97 al measurements should be prioritized in HIV-cure-directed clinical trials.

98 ease with potential to restore function, and cure disease.

99 Importantly, CURE does not deaminate adenosine, enabling the high-spe

100 DAA cure does not promote resurrection of exhausted CD4(+) T

101 and peripheral T-cell lymphoma is potential cure, during which PET is mainly used to assess remissio

102 amics across the human body is important for cure efforts.

103 parasitoid wasp species have been used in a CURE engaging students at 15 colleges and universities.

104 To qualitatively reproduce the GdnHCl curing experiment, aggregate replication must not be com

105 ith reasonable expectation of posttransplant cure, extensive mesenteric vein thrombosis and intestina

106 , sputum conversion, and treatment outcomes (cure, failure, death, or loss to follow-up) were compare

107 s phenomenon is important to advance the HIV cure field.

108 In the absence of a pharmacological cure, finding the most sensitive early cognitive markers

109 Microbial cure following doxycycline-azithromycin was 95.4% (95% c

110 beta cell transplantation offers a potential cure for a subset of diabetic patients.

111 correction presents one of few options for a cure for all patients with cystic fibrosis.

112 te relapse causing dormant cells and offer a cure for cancer.

113 Although there is no effective cure for chronic hepatitis B virus (HBV) infection, anti

114 To date, there is no effective cure for DMD, and the identification of novel molecular

115 lls are the greatest obstacle to obtaining a cure for HIV infection, as these cells can persist despi

116 e effective, antiretroviral therapy is not a cure for HIV infection.

117 Developing a cure for HIV is a global priority.

118 To get a cure for HIV, it is important to identify and characteri

119 V-1) in many patients, currently there is no cure for HIV-1, presumably due to the presence of reserv

120 servoirs is a major challenge in achieving a cure for HIV.

121 There is no cure for MS, but available disease-modifying therapies c

122 iral (DAA) therapy has led to near-universal cure for patients chronically infected with hepatitis C

123 Because there is no cure for SRS, treatment plans focus on alleviating sympt

124 Unfortunately, there is no cure for this disease, which highlights the need for fur

125 There is currently no cure for this disorder.

126 dation, the Major Family Foundation, the Max Cure Foundation, the Richard "Rick" J.

127 Cured fruits reached up to 191.4 +/- 1.4 mg/L of anthocy

128 rove our understanding of human genetics and cure genetic disease.

129 RISPR-mediated gene editing shows promise to cure genetic pathologies, although hitherto it has mostl

130 were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underl

131 e amino acids are naturally generated in dry-cured ham as a consequence of proteolysis phenomenon exe

132 the differences in sensory properties of dry-cured ham between the Montanera and Pienso systems.

133 reviews the recent findings showing that dry-cured ham constitutes a good source of natural bioactive

134 During dry-cured ham processing, phospholipids (PL) are the main su

135 surface decontamination of ready-to-eat dry-cured ham was studied in two Spanish varieties, Serrano

136 enty-first century that remission, let alone cure, has been a regularly achievable target in RA.

137 l of alanine aminotransferase) or functional cure (HBsAg below 0.05 IU/mL, HBV DNA target not detecte

138 The central challenge in curing HBV is eradication of the stable covalently close

139 (DAA) offer an unprecedented opportunity to cure HCV.

140 eously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures

141 portant implications for HCC surveillance in cured HCV patients.

142 might be targeted in the emerging efforts to cure HIV disease.

143 hronic infection, approaches to eradicate or cure HIV infection are desired.

144 servoir must be sought.IMPORTANCE Efforts to cure HIV infection have focused primarily on the elimina

145 d in some PWH interrupting ART.IMPORTANCE To cure HIV, we likely need to target the reservoirs in all

146 tiretroviral therapy suppresses but does not cure HIV-1 infection due to the existence of a long-live

147 RT) is an important milestone for efforts to cure HIV-1 infection.

148 Curing HIV infection will require the elimination of a r

149 d individuals and that is a major barrier to curing HIV infection, the in vivo proliferation of laten

150 on is widely regarded as the main barrier to curing HIV.

151 serve as new targets for therapies aimed at curing HIV.

152 n be used to prevent, manage, and eventually cure IBD.

153 Nevertheless, most malaria cases could be cured if detected early.

154 agents for a SHIV model of HIV-1 latency and cure.IMPORTANCE Simian-human immunodeficiency viruses (S

155 al variation in the percentage of failure to cure, improvement is needed.

156 Treatment with miltefosine resulted in cure in 77 % (20/26) of cases, with cures among all spec

157 erapeutic tools for achieving HBV functional cure in chronically infected humans.

158 Hepatitis C virus cure in coinfection brings monocyte activation to levels

159 ecific for NCC, but also useful as a test of cure in CSF and for the definitive diagnosis of NCC in p

160 nt was driven by both HIV and HCV.SummaryHCV cure in HIV coinfection improves monocyte and plasma act

161 Allogeneic SCT offers a chance for cure in patients with high-risk ALCL relapse.

162 Vinblastine monotherapy achieved cure in patients with late relapse; however, it was not

163 onitoring of parasite load and assessment of cure in PKDL.

164 The differences between remission and cure in RA are first defined, followed by a discussion o

165 as drivers) that prevent the achievement of cure in RA by triggering sustained immune activation and

166 dressing the obstacles to the achievement of cure in RA.

167 This study aimed to describe failure to cure in terms of incidence, hospital variation, and as a

168 fty-three patients (100%) achieved treatment cure in the 6-week group compared with 153 (99.4%) in th

169 aring FR-positive KB human xenografts led to cures in 100% of the test animals with very low dose lev

170 unmodified tumors and lead to a high rate of cures in both subcutaneous and intra-cranial tumor model

171 There is no vaccine or cure, in part due to the ability of HSV to escape the ho

172 elapses that could be prevented with radical cure including a hypnozoitocidal agent; however, the ben

173 suppress HIV-1 replication but are unable to cure infection.

174 re under way to develop therapies capable of curing infection.

175 iremia to study the latent HIV reservoir and cure interventions.

176 atent reservoir and evaluating the impact of cure interventions.

177 Microbiologic cure is a common outcome in pneumonia clinical trials, b

178 A hepatitis C (HCV) cure is associated with changes in lipids and inflammato

179 CCR5Delta32 homozygous donors are used, HIV cure is possible.

180 Cure is the aspirational aim for the treatment of all di

181 ment of a human immunodeficiency virus (HIV) cure is the lack of a scalable animal model that enables

182 The major barrier to a HIV-1 cure is the persistence of latent genomes despite treatm

183 that the probability of remission for life (cure) is 98% in the context of 80% donor chimerism in to

184 as 8 weeks of combined antibiotic therapy in curing lesions without surgery.

185 ation were found between eating nitrated dry cured meat and other psychiatric disorders.

186 found that a history of eating nitrated dry cured meat but not other meat or fish products was stron

187 statectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate

188 Microbiologic cure merits further study as a metric to guide therapeut

189 Oral administration of WM382 cured mice of P. berghei and prevented blood infection f

190 Accordingly, cured mice showed T-cell unresponsiveness to InsB9-23 st

191 f the index pathogen at the time of clinical cure (microbiologic failure) and those with pathogen era

192 ll develop TB disease following infection, a cure model, first introduced by Boag in 1949, should be

193 tails of survival curves, we also exploited "cure models" to estimate the fraction of patients effect

194 Immunotherapy fails to cure most cancer patients.

195 Antibiotics are highly effective in curing Mycobacterium ulcerans lesions, but are associate

196 d at EoT in biopsy specimens of patients who cured (n = 8), compared to those from patients with trea

197 ilot cohort of DNA samples from CL patients (cures, n = 20, and treatment failure, n = 20), showing p

198 , the broad consensus was that an acceptable cure need not be as safe and effective as optimally deli

199 OF/VEL/VOX for the treatment of difficult-to-cure NS5A-inhibitor experienced patients, including thos

200 One-month cure occurred in 200 patients (90%); of these, 197 (98%)

201 ved forward toward clinical application as a cure of cardiac disease.

202 able vaccination strategy for the functional cure of chronic hepatitis B.

203 tive to no FQ-DST, targeted FQ-DST increased cure of FQ-resistant TB by 7.5% (interquartile range [IQ

204 leads to less need for additional therapy or cure of HCL.

205 ch raises the possibility that a sterilizing cure of HIV-1 infection, which has previously been obser

206 itis receiving ART, and implications for the cure of HIV.

207 Can we find its value for the cure of infections?

208 SC-specific mechanisms for the prevention or cure of malignant diseases.

209 motor function through physical activity and cure of seasonal depression with phototherapy.

210 cell transplantation on allergy transfer or cure of the disease.

211 past the 5-year milestone (46.1%) seem to be cured of disease.

212 lied to investigate the edited strains after curing of the base editor plasmid.

213 known inconsistencies in the appearance and curing of yeast prions.

214 timate the fraction of patients effectively "cured" of disease.

215 Although there is no cure or established means of prevention, effective treat

216 oxacin (present in 76.2% of failures vs 7.8% cures, P < .001) or doxycycline-sitafloxacin (50% vs 16.

217 statistically significant higher failure to cure percentages, whereas 2 had lower percentages.

218 with different biopolymer concentrations and curing periods.

219 ollow-up after 24 weeks), whereas functional cure persisted in 14 of 40 participants (all completing

220 et therapies such as PlGF overexpression, to cure placental disorders during pregnancy.

221 o unpleasant compounds were generated in the cured plus cold-stored juice volatilome.

222 raphene on polymer substrates using a direct curing process is demonstrated.

223 wed average pore size of 1mumwith slow (2 h) curing process.

224 ia by re-exposure to all trauma-related cues cures PTSD-like hypermnesia.

225 ttle research has been carried out on how to cure RA, and the term 'cure' still requires definition f

226 The failure to cure rate after salvage surgery was 27.6% in high-volume

227 F and miltefosine was tested to increase the cure rate and decrease the healing time.

228 Although the cure rate for childhood acute lymphoblastic leukemia (AL

229 icacy in CL caused by L. braziliensis with a cure rate of 75%.

230 New therapies that maintain a high cure rate while reducing off-target toxicity are require

231 excision, this approach may result in higher cure rates at a lower cost by allowing same-day reexcisi

232 Cure rates for primary mediastinal large B-cell lymphoma

233 founded, as demonstrated by 90% relapse-free cure rates in FMT treatment for recurrent Clostridioides

234 vorship issues, along with a need for better cure rates in the older patient, the improved survival o

235 use models of breast and colon cancers, with cure rates of 40% and 60%, respectively.

236 erapy has been associated with very high HCV cure rates of up to 100%.

237 ision, this surgical modality has much lower cure rates than Mohs micrographic surgery, likely due to

238 While cure rates were >95% in both treatment arms, the Pfkelch

239 Novel targeted therapies to improve cure rates while minimizing toxicities are urgently need

240 Furthermore, subjective cure rates, although initially high, also deteriorate ov

241 The most effective treatments, with highest cure rates, are also cost-effective due to averted morta

242 tial infection, and subsequent likelihood of cure, recurrence, mortality, and outcomes of subsequent

243 formed for spontaneous spleen rupture, or to cure refractory autoimmune haemolytic anemia.

244 hough potential for this strategy to achieve cure remains uncertain.

245 nowledge on repeat instability mechanisms to cure repeat expansion diseases?

246 An HIV cure requires the elimination of HIV from every body com

247 and describe relevant new work in functional cure research and strategies for HIV-1 eradication.

248 lasma viraemia is a major objective of HIV-1 cure research, but the characteristics of proviral reser

249 al studies and highlight new insights in HIV cure research.

250 adhesion properties among the liquid resin, cured resin, and resin vat.

251 Efficacy assessments included overall cure (resolution of signs of candidemia/IC + mycological

252 Even now, achieving a cure seems to be a rare occurrence among individuals wit

253 easured creatinine at enrollment and test of cure, serum gentamicin concentration postdose to establi

254 cently, advances in immunotherapies that can cure some cancers.

255 These therapeutics have been shown to cure some patients with bladder cancer and significantly

256 carried out on how to cure RA, and the term 'cure' still requires definition for this disease.

257 rs during suppressive ART, suggesting future cure strategies should study interventions to suppress r

258 explore these areas to develop effective HIV cure strategies.

259 ration of CD8 T-cell function is critical in cure strategies.

260 ntiretroviral therapy is critical to develop cure strategies.

261 l strategy to enhance CD8 T-cell function in cure strategies.

262 gs into viable HIV prevention, treatment and cure strategies.

263 s type 1 (HIV-1) vaccines, therapeutics, and cure strategies.

264 nder ART.IMPORTANCE The "shock and kill" HIV cure strategy attempts to reverse and eliminate the late

265 human immunodeficiency virus type 1 (HIV-1) cure strategy involves latency reversal followed by immu

266 ith ART may drive higher rates of functional cure than during HBV monoinfection treatment.

267 professionals made every possible effort to cure the child (P = .01).

268 allic microwire that retains its shape after curing the silicone.

269 Here, we report the development of "CURE", the first cytidine-specific C-to-U RNA Editor.

270 vel HIV-1 treatments leading to a functional cure, the time to viral rebound is frequently used as a

271 oncept into a clinically feasible functional cure therapy.

272 Although most patients are cured, those with disease arising in the mediastinum hav

273 As there is no cure, thousands of individuals who are alive at present

274 cipants (n = 0/69) with a sustained clinical cure through 12 weeks following bezlotoxumab infusion ex

275 a certain biopolymer concentration level and curing time.

276 e, enabling the high-specificity versions of CURE to create fewer missense mutations than RESCUE-S at

277 Such a drug would raise the hope for a cure to many P2X7-dependent pathologies, including infla

278 tor-assessed clinical success at the test-of-cure (TOC) visit.

279 ticipants with normal or high BMIs, rates of cure, treatment failure, or death did not vary by glycem

280 in patients with cancer; with no therapeutic cure, treatments remain largely palliative.

281 sed to determine therapeutic efficacy in HIV cure trials; however, such data were collected from stud

282 We assessed the association between cured tuberculosis (TB) and mortality among persons livi

283 reating recurrent liver failure episodes and cure type 1 diabetes.

284 ell death pathway in cells that successfully cure viral infection.

285 vival curve analysis median healing time for cure was 102 for Sb v group and 60 days for both miltefo

286 of baseline characteristics with failure to cure was analyzed using multivariable logistic regressio

287 Failure to cure was defined as: 1) no surgical resection due to int

288 Cure was reached after supplementation with convalescent

289 Although the minimum attributes for a cure were debated, the broad consensus was that an accep

290 apy) for a target product profile for an HIV cure were identified.

291 Rates of initial clinical cure were similar across eAb titer categories.

292 important for maintaining a functional HIV-1 cure when antiviral therapy is stopped.

293 t resolution of allergies is needed before a cure, where reactivity to the allergen is permanently lo

294 Among 112 patients with initial cure who were followed to 6 months, 4 (4%) had CDI recur

295 eated with MIL monotherapy attained clinical cure with a gradual decrease in parasite load; however,

296 The number needed to treat for a clinical cure with ceftolozane/tazobactam was 5, and the number n

297 causes persistent infections that cannot be cured with conventional antibiotics.

298 actory disease can be effectively treated or cured with high-dose chemotherapy followed by autologous

299 of tumors that encompass both benign tumors cured with surgical resection and highly lethal cancers

300 comonomer additive in otherwise traditional curing workflows, the resulting materials can display th